WO2011057504A1 - Utilisation du récepteur variable des lymphocytes (vlr) d'agnathes dans la préparation d'un médicament - Google Patents

Utilisation du récepteur variable des lymphocytes (vlr) d'agnathes dans la préparation d'un médicament Download PDF

Info

Publication number
WO2011057504A1
WO2011057504A1 PCT/CN2010/075165 CN2010075165W WO2011057504A1 WO 2011057504 A1 WO2011057504 A1 WO 2011057504A1 CN 2010075165 W CN2010075165 W CN 2010075165W WO 2011057504 A1 WO2011057504 A1 WO 2011057504A1
Authority
WO
WIPO (PCT)
Prior art keywords
vlr
lymphocyte receptor
variable lymphocyte
drugs
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2010/075165
Other languages
English (en)
Chinese (zh)
Inventor
李庆伟
吴芬芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liaoning Normal University
Original Assignee
Liaoning Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liaoning Normal University filed Critical Liaoning Normal University
Publication of WO2011057504A1 publication Critical patent/WO2011057504A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to the use of a substance, namely a non-mandibular vertebrate variable lymphocyte receptor (VLR) Use in pharmaceuticals, especially in the manufacture of anti-pathogenic microorganisms, anti-tumor therapeutic drugs and diagnostics.
  • VLR variable lymphocyte receptor
  • Antibacterial drugs are one of the most widely used and widely used drugs in clinical practice and play an important role in the prevention and treatment of infectious diseases.
  • the massive abuse of antibacterial drugs the resistance of pathogenic microorganisms to antibacterial drugs is spreading.
  • the drug In the treatment of infected patients with antibacterial drugs, there are often cases where the drug is ineffective.
  • it is necessary to increase the intensity of control of the abuse of antibacterial drugs, and on the other hand, new antibacterial drugs are urgently needed to supplement.
  • VLR Variable lymphocyte receptor
  • VLR variable lymphocyte receptor
  • the gene is randomly inserted into a leucine-rich repeat unit to form a diverse antigen recognition receptor, which specifically recognizes different antigens and achieves adaptive immunity of the jawless vertebrates.
  • VLR Variable lymphocyte receptor
  • the secretory VLR is a tetramer or pentamer formed by 4 to 5 dimers linked by disulfide bonds. They have 8 to 10 antigen binding sites, respectively. Morphologically, there is a high degree of similarity to higher mammalian IgM.
  • VLR variable lymphocyte receptor affinity for specific antigens IgG
  • the class of antibodies is ten times higher. Its unique characteristics are expected to be applied in anti-microbial infection and anti-tumor diagnosis and treatment like antibody drugs and even better than antibody drugs. To date, no variable lymphocyte receptor (VLR) has been observed. Used in the pharmaceutical field.
  • the present invention finds a variable lymphocyte receptor (VLR) produced by lymphocytes secreted by a vertebrate-free vertebrate It has potential application value in anti-pathogenic microbial infection and anti-tumor treatment and diagnosis.
  • VLR variable lymphocyte receptor
  • variable lymphocyte receptor recognizes and neutralizes Microbiologically, it has stronger specificity and sensitivity than antibodies, and will play a role in the diagnosis and anti-microbial treatment of pathogenic microbial infections. At the same time, under the immune stimulation of specific tumor antigens, this receptor acts on tumor antigens. Its superior affinity makes it a new ideal tool for targeted cancer therapy and diagnosis.
  • VLR variable lymphocyte receptor
  • VLR non-mandibular vertebrate variable lymphocyte receptor
  • VLR Receptors can be used in assembly in vitro diagnostic kits for the diagnosis of pathogenic microbial infections and for tumor discovery, efficacy and prognosis of tumor markers, because their affinity for antigens is ten times higher than that of antibody molecules, so it will It has higher sensitivity and detection specificity than traditional antibody-based diagnostic kits.
  • VLR VLR
  • the recombinant protein and the recombinant protein can be combined with the high specificity and high affinity of the microorganism, and have a neutralizing effect on the microorganism, can prevent the microbial invasion and promote the degradation and elimination thereof, thereby achieving the therapeutic effect.
  • VLR and its recombinant protein have a high specific binding capacity to tumor cells.
  • Will VLR In combination with drugs, enzymes or radioisotopes, VLRs are automatically guided to bind to specific tumor cells or tissues in the body and produce therapeutic effects by the drugs they carry.
  • VLR It has better affinity and specificity than monoclonal antibodies, can accurately target and capture target cells, react specifically with target targets, and will act as a biological missile to achieve unique and superior performance that other drugs cannot achieve. .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'utilisation du récepteur variable des lymphocytes (VLR) d'agnathes dans la préparation d'un médicament, en particulier un médicament utilisé dans le diagnostic ou le traitement de tumeurs et d'infections à micro-organismes pathogènes.
PCT/CN2010/075165 2009-11-13 2010-07-15 Utilisation du récepteur variable des lymphocytes (vlr) d'agnathes dans la préparation d'un médicament Ceased WO2011057504A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910219869A CN101721680A (zh) 2009-11-13 2009-11-13 无颌类脊椎动物可变淋巴细胞受体(vlr)在制药中的应用
CN200910219869.4 2009-11-13

Publications (1)

Publication Number Publication Date
WO2011057504A1 true WO2011057504A1 (fr) 2011-05-19

Family

ID=42443628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/075165 Ceased WO2011057504A1 (fr) 2009-11-13 2010-07-15 Utilisation du récepteur variable des lymphocytes (vlr) d'agnathes dans la préparation d'un médicament

Country Status (2)

Country Link
CN (1) CN101721680A (fr)
WO (1) WO2011057504A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101721680A (zh) * 2009-11-13 2010-06-09 辽宁师范大学 无颌类脊椎动物可变淋巴细胞受体(vlr)在制药中的应用
CN103033617B (zh) * 2012-11-30 2014-12-03 辽宁师范大学 基于可变淋巴细胞受体的肿瘤标志物检测试剂盒及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083275A2 (fr) * 2004-05-21 2006-08-10 The Uab Research Foundation Recepteurs de lymphocytes variables, polypeptides et acides nucleiques associes, et leurs utilisations
CN101721680A (zh) * 2009-11-13 2010-06-09 辽宁师范大学 无颌类脊椎动物可变淋巴细胞受体(vlr)在制药中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083275A2 (fr) * 2004-05-21 2006-08-10 The Uab Research Foundation Recepteurs de lymphocytes variables, polypeptides et acides nucleiques associes, et leurs utilisations
CN101721680A (zh) * 2009-11-13 2010-06-09 辽宁师范大学 无颌类脊椎动物可变淋巴细胞受体(vlr)在制药中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRANTLEY R. HERRIN ET AL.: "Structure and specificity of lamprey monoclonal antibodies", PNAS, vol. 105, no. 6, 12 February 2008 (2008-02-12), pages 2041 - 2045 *
MAX D. COOPER: "A Life of Adventure in Immunobiology", ANNUAL REVIEW OF IMMUNOLOGY, vol. 28, 16 October 2009 (2009-10-16), pages 1 - 19 *
SATOSHI TASUMI ET AL.: "High-affinity lamprey VLRA and VLRB monoclonal antibodies", PNAS, vol. 106, no. 31, 4 August 2009 (2009-08-04), pages 12891 - 12896, XP055049062, DOI: doi:10.1073/pnas.0904443106 *

Also Published As

Publication number Publication date
CN101721680A (zh) 2010-06-09

Similar Documents

Publication Publication Date Title
Elieh Ali Komi et al. Mast cell biology at molecular level: a comprehensive review
CN113490686B (zh) 病原体结合蛋白
Gil et al. Biofilm matrix exoproteins induce a protective immune response against Staphylococcus aureus biofilm infection
Signat et al. Role of Fusobacterium nucleatum in periodontal health and disease
Ukena et al. The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1
BRPI0408315A (pt) anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
CA2769394C (fr) Anticorps monoclonal humain contre l'alpha-toxine derivee de s. aureus et son utilisation dans le traitement ou la prevention de la formation d'abces
WO2008031133A3 (fr) Antigènes de borrelia
WO2022262101A1 (fr) Anticorps anti-cd70 présentant un effet adcc amélioré et application associée
Liu et al. Preparation of a nanobody specific to dectin 1 and its anti-inflammatory effects on fungal keratitis
Liu Enterotoxin-producing Staphylococcus aureus
JP2020506221A5 (fr)
CN118684735B (zh) 特异性靶向cd5的环肽分子及其用途
RU2011140508A (ru) Антигены хламидии
Cutino‐Moguel et al. Immunotherapy for infectious diseases in haematological immunocompromise
FI4230650T3 (fi) Vasta-aineet, jotka kykenevät sitoutumaan koronavirus sars-cov-2:n piikkiproteiiniin
Suresh et al. Prevalence and characterization of virulence-associated genes and antimicrobial resistance in Aeromonas hydrophila from freshwater finfish farms in Andhra Pradesh, India
Bessho et al. Systemic exposure to bacterial amyloid curli alters the gut mucosal immune response and the microbiome, exacerbating Salmonella-induced arthritis
Jin et al. Modulation of ovine SBD-1 expression by Saccharomyces cerevisiae in ovine ruminal epithelial cells
WO2011057504A1 (fr) Utilisation du récepteur variable des lymphocytes (vlr) d'agnathes dans la préparation d'un médicament
Yang et al. Saccharomyces boulardii administration can inhibit the formation of gastric lymphoid follicles induced by Helicobacter suis infection
CN104211804A (zh) 一种抗金黄色葡萄球菌多克隆抗体的制备与应用
Voss et al. Discovery of antimicrobial peptides in urinary tract infections
Tian et al. Virulence factors and mechanisms of paediatric pneumonia caused by Enterococcus faecalis
GB2623253A (en) Klebsiella pneumoniae KlebC polypeptides and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10829468

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10829468

Country of ref document: EP

Kind code of ref document: A1